The Health, Science & Technology (HST) Group aims to further improve the investment climate for the pharmaceutical industry in Belgium. To this end, the group regularly consults the ministers in charge on topics such as business environment and investments, reimbursement policies and prices, the potential of the sector in the recovery policy, intellectual property and international trade agreements. In 2013 the group prepared various policy recommendations for the federal government. 

The HST Group also pays special attention to the training of young people, to development collaboration, to an even more intense collaboration between industry and the academic world, and to rapid and optimal access to innovative medicines. 


The HST Group was created in 2006 by Janssen Pharmaceutica NV, UCB, GlaxoSmithKline and Pfizer, all of which invest heavily in research & development in Belgium, and therefore play a major role in the Belgian economy and the employment situation.

Investments in Research & Development are seen as an incentive for (high quality) employment, export and economic growth. Belgium is also an important market for clinical studies in Europe. The report concludes that, with a view to the future, it is important to maintain, and even improve, the competitive advantage of the Belgian biopharmaceutical sector.

 It is important to maintain, and even improve, the competitive advantage of the Belgian biopharmaceutical sector.


Janssen believes that strong corporate results, correct policies and focused activities pave the way towards economic sustainability. 

Janssen must constantly reinvent itself in order to cope with the structural and economic changes that affect its environment. This is why Janssen is committed to build partnerships within an open innovation model, and to the continuous alignment of its cost-competitiveness by only developing medicines with a high therapeutic added value. 

For Janssen this means specifically: being focused and a leader in research & development, and being efficient and progressive in terms of production with the aim of bringing new therapeutic solutions to patients quicker and at less expense, and implementing a growth strategy to ensure our continued investment in all these areas.